Hossack Lab is a group of researchers who study ultrasound and ultrasound contrast agents to advance innovative applications in disease diagnosis, treatment, and monitoring. Alumni from Hossack lab have been successful in finding positions as post-docs in leading ultrasound research laboratories and in all big three medical imaging companies (GE, Philips and Siemens) and startup companies.
UPDATE (11/13/17): New NIH grant pending
Hossack Laboratory recently received a top 10% score on a new four-year R01 grant application to investigate catheter-based generation of special-purpose microbubbles for rapid erosion of embolic clots. Venous thromboembolism (VTE), comprising Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), results in significant mortality, morbidity, and societal cost. There are approximately 900,000 recurrent, fatal and nonfatal VTE events resulting in 300,000 deaths annually in the US.
With this four-year grant, extendable to five years, Hossack Lab will be supported by two R01s, and thus will have secure funding for the duration of incoming PhD students. Additionally, Hossack Lab receives significant support from two NIH grants to UVA colleagues, Dr. Sasha Klibanov and Dr. Mark Okusa, with projects involving ultrasound molecular imaging and ultrasound-based therapies for ischemia-reperfusion injury, respectively. The lab has also had a highly successful record with smaller grants such as the Coulter Partnership grant, funded by the Coulter endowment to the UVA BME department, investigating the capabilities of ultrasound for breast cancer therapy monitoring. Taken together, Hossack Lab is well-positioned to grow and thrive in the coming years despite the challenging funding environment.